Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

by Zacks Equity Research

The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA

Zacks Equity Research

The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI

by Zacks Equity Research

The Zacks Analyst Blog Highlights: CLX, MRNA, TDOC and ATVI

Kinjel Shah headshot

Pfizer, Regeneron Give Update on Coronavirus Drug Development

by Kinjel Shah

Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.

Urmimala Biswas headshot

3 Medical Stocks Poised to Trounce Market on Coronavirus Scare

by Urmimala Biswas

Here are three Medical stocks showing early signs of stellar growth, banking on the choppy global market scenario.

Tirthankar Chakraborty headshot

Hopes of a COVID-19 Vaccine Buoy Drug Makers: 3 Solid Buys

by Tirthankar Chakraborty

Shares of Moderna soared higher after the company dosed a patient with a vaccine against the novel coronavirus in the Phase 1 study. This, calls for investing in companies racing to develop a vaccine against COVID-19

Zacks Equity Research

Moderna (MRNA) Catches Eye: Stock Jumps 6.4%

by Zacks Equity Research

Moderna (MRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Zacks Equity Research

Is Moderna (MRNA) Stock a Solid Choice Right Now?

by Zacks Equity Research

Moderna (MRNA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Zacks Equity Research

Mallinckrodt Completes NDA Submission for Kidney Failure Drug

by Zacks Equity Research

Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.

Madeleine Johnson headshot

These 10 Drug Companies are Testing a Coronavirus Vaccine

by Madeleine Johnson

As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Kinjel Shah headshot

Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection

by Kinjel Shah

A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.